India’s Lupin Plans Expansion Into Cardiology, Neurology Generics
This article was originally published in PharmAsia News
Lupin Laboratories, ranked fifth in size of Indian drug makers, plans to expand its formulations business so it can move into new generics markets in the country. The new focus areas for Lupin are cardiology and neurology, building on its recent expansion into cancer care and diabetes formulations. The entry into oncology drugs was launched last quarter. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.